A NOVEL MECHANISM OF ANDROGEN RECEPTOR ACTION

雄激素受体作用的新机制

• 批准号: 7958495
• 负责人: Charles T Roberts
• 金额: $ 8.03万
• 依托单位: OREGON HEALTH & SCIENCE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-08-04 至 2010-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7958495
• 关键词: Androgen Receptor; Clinical; Computer Retrieval of Information on Scientific Projects Database; ERBB2 gene; Funding; Goals; Grant; Institution; Malignant neoplasm of prostate; PC3 cell line; Primates; Regulation; Research; Research Personnel; Resources; Sampling; Source; United States National Institutes of Health; Variant; cancer cell; herstatin; novel

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The goal of this project is the characterization of the effects of a novel HER-2 variant (herstatin) on IGF-IR action in prostate cancer. The revised aims of this project are to: 1. Characterize the effects of herstatin in prostate cancer cells. 2. Evaluate expression of herstatin in prostate cancer cell lines and clinical samples. 3. Investigate regulation of herstatin expression.

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 该项目的目标是描述一种新的HER-2变异体(Herstatin)对前列腺癌中IGF-IR作用的影响。该项目的修订目标是： 1.研究Herstatin对前列腺癌细胞的作用。 2.检测前列腺癌细胞株和临床标本中Herstatin的表达。 3.研究Herstatin的表达调控。